Jane Street Group LLC Acquires 255,028 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Jane Street Group LLC increased its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 338.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 330,442 shares of the company's stock after acquiring an additional 255,028 shares during the quarter. Jane Street Group LLC owned about 0.62% of Stoke Therapeutics worth $4,061,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company's stock worth $936,000 after acquiring an additional 71,647 shares during the period. RTW Investments LP boosted its position in shares of Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock worth $57,177,000 after purchasing an additional 427,447 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Stoke Therapeutics by 54.3% during the third quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company's stock worth $1,266,000 after purchasing an additional 36,240 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Stoke Therapeutics by 426.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock valued at $18,741,000 after purchasing an additional 1,123,500 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Stoke Therapeutics by 528.6% in the second quarter. Millennium Management LLC now owns 289,067 shares of the company's stock valued at $3,905,000 after buying an additional 243,083 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on STOK shares. Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. HC Wainwright reissued a "buy" rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, Leerink Partners assumed coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an "outperform" rating and a $18.00 price objective for the company. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $20.83.

Stoke Therapeutics Stock Up 1.7 %

STOK traded up $0.19 during trading on Thursday, hitting $11.30. The company had a trading volume of 768,999 shares, compared to its average volume of 742,928. The company has a market capitalization of $598.53 million, a PE ratio of -5.38 and a beta of 0.95. Stoke Therapeutics, Inc. has a one year low of $4.09 and a one year high of $17.58. The firm's 50-day moving average price is $12.49 and its 200 day moving average price is $13.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, CEO Edward M. Md Kaye sold 6,786 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $88,150.14. Following the completion of the transaction, the chief executive officer now directly owns 61,885 shares in the company, valued at $803,886.15. This represents a 9.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Barry Ticho sold 10,000 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares of the company's stock, valued at $618,913.39. The trade was a 16.32 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 62,849 shares of company stock worth $809,421. Corporate insiders own 11.30% of the company's stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.